AstraZeneca PLC ADR (AZN)

63.52
+0.08(+0.13%)
After Hours
63.40
-0.12(-0.19%)
- Real-time Data
  • Volume:
    4,697,062
  • Day's Range:
    63.21 - 63.85
  • 52 wk Range:
    52.65 - 72.12
Earnings results expected in 3 days

AstraZeneca ADR will announce its quarterly financial results in 3 days. Traders should take this into account as the share price often fluctuates around this time period.

AZN Overview

Prev. Close
63.44
Day's Range
63.21-63.85
Revenue
33.14B
Open
63.58
52 wk Range
52.65-72.12
EPS
1.32
Volume
4,697,062
Market Cap
197.03B
Dividend (Yield)
1.42
(2.24%)
Average Vol. (3m)
5,115,080
P/E Ratio
107.74
Beta
0.231
1-Year Change
13.85%
Shares Outstanding
1,549,800,030
Next Earnings Date
Feb 09, 2023
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100

AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.

Read More

Analyst Price Target

Average76.67 (+20.70% Upside)
High88.00
Low65.00
Price63.52
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellBuy
Technical IndicatorsSellSellBuyStrong SellBuy
SummaryNeutralSellNeutralStrong SellBuy
  • did they develop a vaccine that works now or why is thos going up?
    0
    • Valneva
      0
      • why this trash going up?
        3
        • speculation
          0
      • already breakout guy.
        0
        • I would await some further drop based on the below article to come in the near future. The company did not perform well with the vaccine and i opened some short positions if my assumptions are correct.
          0
          • https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/603675/astrazenecas-covid-troubles-could-see-it-pull
            0
            • hold long = big victory ✌
              0
              • Finally it reached $60+.
                0
                • AZN and MRK: Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. Support is strong for the 2 stocks.
                  0
                  • the Delta virus already in USA, but the CDC covered up the truth. in this next 2 weeks, millions of people will get infected, many states may lockdown again.
                    1